Becton Dickinson (BD) Marketcap, Revenue, Net Worth, Competitors 2026

Becton Dickinson Key Stats

Becton, Dickinson and Company, commonly known as BD, is an American multinational medical technology company headquartered in Franklin Lakes, New Jersey. The company develops, manufactures, and sells medical devices, instrument systems, laboratory equipment, and diagnostic products.

BD serves healthcare institutions, physicians, life science researchers, clinical laboratories, and the pharmaceutical industry. The company operates through three primary segments: BD Medical, BD Life Sciences, and BD Interventional.

As one of the largest medical technology companies globally, BD focuses on improving medical discovery, diagnostics, and the delivery of care. Similar to other healthcare giants like Medtronic, BD plays a critical role in advancing healthcare solutions worldwide.

Becton Dickinson History

The history of Becton Dickinson spans more than 125 years of innovation in medical technology. The company has grown from a small partnership selling medical thermometers to a global leader in healthcare solutions.

Becton Dickinson Co-founders

Becton Dickinson was founded by two experienced salesmen who saw an opportunity in the growing American healthcare market. Their partnership laid the foundation for one of the most successful medical technology companies in history.

Becton Dickinson Competitors

Becton Dickinson operates in a competitive landscape that includes several major medical technology and healthcare companies. BD competes across multiple segments including medical devices, diagnostics, and life sciences.

The medical device industry continues to grow with increasing demand for innovative healthcare solutions. Companies like Boston Scientific and Zimmer Biomet compete in various segments of this market.

Becton Dickinson Revenue

Becton Dickinson has demonstrated consistent revenue growth over the past decade. The company reported $20.2 billion in revenue for fiscal year 2024, representing a 4.2% increase from the previous year.

BD’s revenue growth has been driven by organic expansion and strategic acquisitions. Healthcare distributors like Cardinal Health work alongside BD to deliver medical products to healthcare facilities.

Becton Dickinson Market Cap

Becton Dickinson maintains a market capitalization of approximately $56 billion as of late 2024. This positions BD among the largest publicly traded medical technology companies globally.

The company’s market value has fluctuated over the years based on financial performance, acquisitions, and broader market conditions. Companies in the medical technology sector, including Thermo Fisher Scientific, have seen similar market dynamics.

Becton Dickinson Acquisitions

Becton Dickinson has pursued a strategic acquisition approach to expand its product portfolio and market presence. These acquisitions have transformed BD from a medical supplies company into a comprehensive healthcare solutions provider.

The CareFusion acquisition in 2015 marked a significant milestone in BD’s history. BD agreed to pay $12.2 billion to acquire CareFusion Corporation, which specialized in medication management and patient safety solutions. This deal brought infusion pumps, dispensing systems, and respiratory care products into BD’s portfolio.

In 2017, BD completed its largest acquisition by purchasing C.R. Bard for $24 billion. Bard brought expertise in vascular access, urology, oncology, and surgical specialty products. This acquisition created a more diversified medical technology company with expanded capabilities in treating various disease states. The combined company gained a stronger presence in emerging markets with approximately $1 billion in annual revenue from China alone.

The most recent major acquisition came in September 2024 when BD purchased Edwards Lifesciences’ Critical Care product group for $4.2 billion in cash. This division, now renamed BD Advanced Patient Monitoring, adds advanced monitoring technologies and AI-enabled clinical decision tools to BD’s smart connected care portfolio. The acquisition strengthens BD’s position in the intensive care and operating room settings. Similar to how Baxter International has expanded through acquisitions, BD continues to grow its capabilities through strategic purchases.